Articles Written by:    CHINABIO TODAY     

« Previous  |  Next »

GlaxoSmithKline Takes 'Three-Pronged' Approach in China to Fight H1N1 Flu

GlaxoSmithKline (NYSE: GSK) will begin manufacturing its treatment for flu, Relenza, in China to supply China’s domestic market. GSK received approval of the drug in September from the SFDA. Relenza, like Tamiflu from Roche (RHHBY.PK), aims at reducing ...

From CHINABIO TODAY, ETF Investor,  22 Nov 2009
Related Topics: GlaxoSmithKline Inc,  NYSE

China Cord Blood Completes Secondary Offering on NYSE

CO) listed its ordinary shares on the New York Stock Exchange and, at the same time, completed a secondary offering. The company placed 3.3 million shares at a price of $6.05 for gross proceeds of $20 million. China allows one cord blood collection ...

From CHINABIO TODAY, ETF Investor,  22 Nov 2009
Related Topics: NYSE,  New York Stock Exchange

Pfizer Is Best Positioned Big Pharma in China - Goldman

In an investment review of Pfizer (NYSE: PFE), Goldman Sachs said sales in emerging growth markets would become a significant factor in the company’s revenues, a fact that it considers underappreciated by stock market investors. China is the major ...

From CHINABIO TODAY, Seeking Alpha,  20 Nov 2009
Related Topics: Pfizer Inc.,  NYSE,  Goldman Sachs

American Oriental's Q3 Disappoints Again

American Oriental Bioengineering (NYSE: AOB) reported its Q3 revenues rose 12% to $78.8 million but net income fell 39% to $10.0 million. Though the company had a list of reasons for the decline, the mixed nature of American Oriental’s financial ...

From CHINABIO TODAY, ETF Investor,  18 Nov 2009
Related Topics: NYSE

Oculus Wins China Approval for Animal Wound Product

Oculus Innovative Sciences (NSDQ: OCLS) of California reported that its partners have received China regulatory approval to market its wound healing solution as an animal product. Based on the company’s Microcyn technology, Vetericyn products speed the ...

From CHINABIO TODAY, The China Stock Blog,  17 Nov 2009
Related Topics: Bayer

China Medicine Is Already Seeing Benefits from Healthcare Reform

In its Q3 earnings report, China Medicine Corporation (CHME.OB) announced it signed a preliminary non-binding term sheet with a private equity firm that would raise up to $59.5 million for the company. Together with a solid earnings statement, the news ...

From CHINABIO TODAY, The China Stock Blog,  17 Nov 2009

China Medical Wins Approval for Leukemia FISH Probe

China Medical Technologies (NSDQ: CMED) received SFDA approval for its Leukemia BCR/ABL fusion gene detection FISH Probe. The probe uses DNA probes to detect Philadelphia translocation, a chromosomal abnormality associated with three forms of leukemia. ...

From CHINABIO TODAY, Seeking Alpha,  10 Nov 2009

Novartis Seeks to Make China One of Its Top Three Global Markets

Novartis (NYSE: NVS) of Switzerland will begin a five-year, $1 billion China initiative with two aims: the company will dramatically increase its investment in its China R&D facility, and it will seek to make China one its top three markets worldwide. ...

From CHINABIO TODAY, Seeking Alpha,  4 Nov 2009
Related Topics: Novartis,  NYSE,  Daniel Vasella,  Wall Street Journal

Sinovac Set to Move Listing to NASDAQ

Sinovac Biotech Ltd. (SVA) will move the home for its stock listing from the NYSE Amex to the NASDAQ Global Market. The reason given for the change was “greater liquidity.” Target day for the transfer is November 16. Although most NASDAQ companies use ...

From CHINABIO TODAY, Seeking Alpha,  4 Nov 2009
Related Topics: NASDAQ,  NYSE

NeoStem Closes China Biopharma Acquisition to Boost Revenues

NeoStem, Inc. (NBS) announced it has closed its acquisition of China Biopharmaceuticals Holdings, Inc. (CHBP.OB). China Biopharma’s sole asset is a 51% stake in Suzhou Erye Pharmaceutical Co., a 50-year old pharmaceutical company that expects to ...

From CHINABIO TODAY, Seeking Alpha,  3 Nov 2009

« Previous  |  Next »

Who is This?

Help us add to our database, by linking this writer their entry in Wikipedia or Source Watch, or by suggesting that we remove it from our index.

Suggest an Entry

Enter a url from sourcewatch.org or wikipedia.org:


recommend removal

close